CLNN

⚡ 1-Minute Take

Data sources: market data, fundamentals, news providers. Data may be delayed.

Key Statistics

📰 Latest News

Clene Inc. pioneers clean-surfaced nanotechnology therapeutics, targeting neurodegenerative diseases with its lead drug CNM-Au8, currently in clinical trials for ALS, Multiple Sclerosis, and Parkinson's Disease, representing a novel approach in a high-growth biotech sector.

About CLNN

Clene Inc. is a clinical-stage pharmaceutical company focused on developing clean-surfaced nanotechnology (CSN) therapeutics. Their lead drug, CNM-Au8, is undergoing clinical trials for ALS, Multiple Sclerosis, and Parkinson's Disease.

Clene Inc. Company Overview

Clene Inc., headquartered in Salt Lake City, Utah, is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The company's core technology revolves around creating and utilizing unique metallic nanocrystals with clean surfaces to address unmet medical needs. Clene's lead drug candidate, CNM-Au8, is at the forefront of its clinical development programs. CNM-Au8 is currently being evaluated in a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis (ALS), reflecting the company's commitment to addressing this debilitating neurodegenerative disease. The company has also completed a Phase 2 proof of concept clinical trial in patients with early symptomatic ALS. Furthermore, CNM-Au8 has been the subject of two completed open-label investigator blinded Phase 2 clinical trials focusing on the brain's energy metabolites. Clene is also pursuing the potential of CNM-Au8 in other neurological conditions, with an ongoing Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis, and a planned Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. Beyond CNM-Au8, Clene is developing a pipeline of other CSN therapeutics, including CNM-AgZn17, a gel polymer suspension of silver and zinc ions for infectious diseases and wound healing; CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent for infection disease, such as COVID-19; and CNM-PtAu7, a gold-platinum CSN therapeutic for oncology applications. The company also markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles.

Investment Thesis

Clene Inc. presents a compelling investment opportunity due to its innovative clean-surfaced nanotechnology (CSN) platform and the potential of its lead drug candidate, CNM-Au8. The ongoing Phase 2/3 registrational clinical trial for ALS represents a significant near-term catalyst. Positive results could lead to accelerated regulatory approval and commercialization, driving substantial revenue growth. Furthermore, the expansion of CNM-Au8 into other neurological indications, such as Multiple Sclerosis and Parkinson's Disease, provides additional upside potential. The company's high gross margin of 82.2% suggests strong pricing power and profitability potential upon commercialization. With a market cap of $0.04B and a Beta of 0.68, CLNN offers a unique risk/reward profile within the biotech sector.

Key Financial Highlights

• Market Cap of $0.04B reflects the company's current valuation and potential for growth.
• Gross Margin of 82.2% indicates strong pricing power and efficient cost management.
• Beta of 0.68 suggests lower volatility compared to the overall market.
• CNM-Au8 is in Phase 2/3 clinical trials for ALS, representing a significant near-term catalyst.
• The company's focus on clean-surfaced nanotechnology (CSN) provides a differentiated approach to drug development.

Industry Context

Clene Inc. operates within the competitive biotechnology industry, which is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. The market for neurodegenerative disease treatments, such as ALS, Multiple Sclerosis, and Parkinson's Disease, is substantial and growing, driven by an aging population and increasing prevalence of these conditions. Clene's CSN platform offers a differentiated approach compared to traditional drug development methods, potentially providing a competitive advantage. Competitors include companies like CohBar (CNTB), Context Therapeutics (CNTX), and COYA Therapeutics (COYA), each pursuing different approaches to address similar therapeutic areas.

Growth Opportunities

• CNM-Au8 for ALS: The successful completion and commercialization of CNM-Au8 for ALS represents a significant growth opportunity. The ALS market is estimated to reach billions of dollars in the coming years, and a breakthrough therapy could capture a substantial share. Timeline: Potential FDA approval within the next 2-3 years, contingent on positive clinical trial results. Competitive advantage: CNM-Au8's unique mechanism of action and potential to improve neuronal survival.
• Expansion into Multiple Sclerosis: The ongoing Phase 2 clinical trial for Multiple Sclerosis offers another avenue for growth. The MS market is also substantial, and a remyelinating therapy could address a significant unmet need. Timeline: Clinical trial data expected within the next 1-2 years. Competitive advantage: CNM-Au8's potential to promote remyelination and restore neurological function.
• Development of CNM-ZnAg for Infectious Diseases: CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent, has the potential to address a wide range of infectious diseases, including COVID-19. The market for antiviral and antibacterial therapies is substantial and growing, driven by emerging infectious diseases and antibiotic resistance. Timeline: Ongoing development and potential for clinical trials in the near term. Competitive advantage: CNM-ZnAg's broad-spectrum activity and potential to provide immune support.
• CNM-AgZn17 for Wound Healing: CNM-AgZn17, a gel polymer suspension of silver and zinc ions, is being developed for wound healing applications. The wound care market is substantial and growing, driven by an aging population and increasing prevalence of chronic wounds. Timeline: Ongoing development and potential for clinical trials in the near term. Competitive advantage: CNM-AgZn17's potential to accelerate wound healing and prevent infection.
• Partnerships and Collaborations: Clene can pursue strategic partnerships and collaborations with larger pharmaceutical companies to accelerate the development and commercialization of its CSN therapeutics. These partnerships could provide access to additional funding, expertise, and resources. Timeline: Ongoing efforts to establish partnerships. Competitive advantage: Clene's innovative CSN platform and promising clinical pipeline.

Competitive Advantages

• Proprietary Clean-Surfaced Nanotechnology (CSN) platform.
• Patent protection for CNM-Au8 and other drug candidates.
• Clinical trial data demonstrating the potential efficacy of CNM-Au8.
• Experienced management team with expertise in nanotechnology and drug development.

Strengths

• Innovative clean-surfaced nanotechnology (CSN) platform.
• Lead drug candidate, CNM-Au8, in Phase 2/3 clinical trials for ALS.
• High gross margin of 82.2%.
• Experienced management team.

Weaknesses

• Clinical-stage company with no currently approved products.
• High operating losses and negative profit margin (-14250.5%).
• Reliance on successful clinical trial outcomes.
• Limited financial resources.

Opportunities

• Expansion of CNM-Au8 into other neurological indications (Multiple Sclerosis, Parkinson's Disease).
• Development of CNM-ZnAg for infectious diseases.
• Partnerships and collaborations with larger pharmaceutical companies.
• Potential for breakthrough therapies in areas with unmet medical needs.

Threats

• Clinical trial failures.
• Regulatory hurdles and delays.
• Competition from other pharmaceutical companies.
• Need to raise additional capital.

What CLNN Does

• Develop clean-surfaced nanotechnology (CSN) therapeutics.
• Focus on treating neurodegenerative diseases like ALS, Multiple Sclerosis, and Parkinson's Disease.
• Conduct clinical trials to evaluate the safety and efficacy of their drug candidates.
• Develop antiviral and antibacterial agents for infectious diseases.
• Develop treatments to accelerate wound healing.
• Market and distribute dietary supplements.

Business Model

• Develop and patent novel CSN therapeutics.
• Conduct clinical trials to obtain regulatory approval.
• Commercialize approved drugs through direct sales or partnerships.
• Generate revenue from the sale of dietary supplements.
• Potentially license out their technology to other companies.

Key Customers

• Patients with neurodegenerative diseases (ALS, Multiple Sclerosis, Parkinson's Disease).
• Patients with infectious diseases.
• Patients with wounds.
• Consumers of dietary supplements.

Competitors

• CohBar (CNTB): Focuses on developing mitochondria-based therapeutics.
• Context Therapeutics (CNTX): Develops therapies for hormone-driven cancers.
• COYA Therapeutics (COYA): Develops Treg cell therapies for neuroinflammation and autoimmune diseases.
• MacroGenics (MGNX): Develops antibody-based therapeutics for cancer.
• Oramed Pharmaceuticals (ORMP): Focuses on oral drug delivery systems.

Catalysts

• Upcoming: Data readout from the Phase 2/3 registrational clinical trial of CNM-Au8 for ALS.
• Upcoming: Initiation of the Phase 2 clinical trial of CNM-Au8 for Parkinson's Disease.
• Ongoing: Progress in the Phase 2 clinical trial of CNM-Au8 for Multiple Sclerosis.
• Ongoing: Development of CNM-ZnAg for infectious diseases.

Risks

• Potential: Clinical trial failures could significantly impact the company's valuation.
• Potential: Regulatory delays or non-approval of CNM-Au8.
• Potential: Competition from other companies developing therapies for the same indications.
• Ongoing: The company's high operating losses and negative profit margin raise concerns about its financial sustainability.
• Ongoing: The need to raise additional capital could dilute existing shareholders.

FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Related Stocks in Biotechnology

Browse More

Next Steps